PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement

PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering $1.5 billion from the Evrysdi royalty stream. ... Read More